KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EPS (Basic): 2011-2025

Historic EPS (Basic) for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $0.29.

  • Travere Therapeutics' EPS (Basic) rose 141.43% to $0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.03, marking a year-over-year increase of 77.36%. This contributed to the annual value of -$4.08 for FY2024, which is 19.53% up from last year.
  • Travere Therapeutics' EPS (Basic) amounted to $0.29 in Q3 2025, which was up 307.14% from -$0.14 recorded in Q2 2025.
  • Travere Therapeutics' 5-year EPS (Basic) high stood at $1.97 for Q3 2023, and its period low was -$1.76 during Q1 2024.
  • Moreover, its 3-year median value for EPS (Basic) was -$0.71 (2024), whereas its average is -$0.58.
  • Per our database at Business Quant, Travere Therapeutics' EPS (Basic) slumped by 4,900.00% in 2021 and then skyrocketed by 250.38% in 2023.
  • Quarterly analysis of 5 years shows Travere Therapeutics' EPS (Basic) stood at -$1.46 in 2021, then climbed by 8.90% to -$1.33 in 2022, then grew by 11.28% to -$1.18 in 2023, then soared by 39.83% to -$0.71 in 2024, then surged by 141.43% to $0.29 in 2025.
  • Its last three reported values are $0.29 in Q3 2025, -$0.14 for Q2 2025, and -$0.47 during Q1 2025.